Author Archives: Blue Sky Science

OHSU Rhesus macaque embryo research to improve Preimplantation Genetic Diagnosis

Preimplantation Genetic Diagnosis is used by parents to screen embryos produced through in-vitro fertilization (IVF) in order to ensure that the baby will be free of specific genetic diseases.  New research from Oregon Health and Science University on the inheritance of the mitochondrial genome indicates that screening for genetic mutations that are located in the genome of the mitochondria – which is outside the nucleus of the cell where the much larger chromosomal genome id found, and is inherited only from the mother – can be made more accurate by carrying out the screening procedure slightly later than is now the practice.

Dr. Shoukhrat Mitalipov, who led this research project, explains what the project involved and its implications

A press release from OHSU highlights the importance of the Rhesus macaque to this discovery about the inheritance of mitochondial genomes:

“This latest breakthrough, which was conducted in rhesus macaque monkeys because of their similarity to humans, demonstrates the specific stage of early embryonic development when genetic mutations are passed from mother to fetus. This stage, referred to by scientists as “the bottleneck,” occurs when an early embryo called blastocyst, transitions into a fetus.

To conduct the research, Mitalipov and colleagues needed to design a way to mark and track specific mitochondrial genes as they transitioned from egg, through fertilization, to embryo and then to fetus. This was accomplished by combining two separate mitochondrial genomes into one egg cell. More specifically, one-half of an egg cell from a species of Indian-continent rhesus macaque monkey was merged with one-half of an egg cell from a Chinese-continent monkey. Because these animal species have distinct mitochondrial gene sequences (like breeding two distinct species of dogs), their genetics could be tracked closely.

The microscopic manipulation of splitting and uniting two halved egg cells takes specialized skills and expertise, which the Mitalipov lab has developed over a period of several years.

By studying the development of these joined and then fertilized eggs, scientists were surprised to see that eggs transitioned from containing a 50/50 split of genetics to a fetus that contained a nearly 100 percent either Indian or Chinese-based genome.

 We discovered that during early development, each individual cell in the eight-cell embryo would contain varying percentages of the Indian and Chinese rhesus genes. Some would be a 50/50 split. But others would be 90/10 and so on,” explained Mitalipov. “When these percentages were combined as a whole embryo, the average genetic split between the two species was about equal as initially created. However, later during the transition from a blastocyst to fetus, the genetics would swing one way or another. The resulting offspring would have always a genome that is predominantly Chinese or Indian. Our study tells us precisely when this mitochondrial gene switch occurs and how this can lead to disease.”

This finding raises significant questions about validity of currently methods for genetic diagnosis in early embryos, when a woman is known to carry a mitochondrial gene mutation may pass a disease to her children.

The current pre-implantation genetic diagnosis method is to examine genetic disease risk is by taking one cell from an early eight-cell embryo, and then looking for mutations in that one particular cell. This is done to predict if the remaining embryo is mutation-free,” explained Mitalipov.

The problem with this approach is that you may choose a cell that may not have mutations. But that does not mean the remaining cells in an embryo are mutation-free. Our research suggests that such approach could be flawed because diagnosis takes place prior to the stage when an offspring’s mitochondrial genetics is truly established.”

With this new information and with additional data gathered through further research, Mitalipov and colleagues believe that new methods for genetic diagnosis for mitochondrial disease should be located. The research also demonstrates that the Mitalipov lab’s previously developed method for preventing the passing of mitochondrial mutations from mother to child is highly successful.”

It’s an important discovery, one with important implications for preimplantation genetic diagnosis, and we congratulate Dr. Mitalipov and his colleagues at OHSU on their success!

Lee, H., Ma, H., Juanes, R., Tachibana, M., Sparman, M., Woodward, J., Ramsey, C., Xu, J., Kang, E., Amato, P., Mair, G., Steinborn, R., & Mitalipov, S. (2012). Rapid Mitochondrial DNA Segregation in Primate Preimplantation Embryos Precedes Somatic and Germline Bottleneck Cell Reports DOI: 10.1016/j.celrep.2012.03.011

What GM mice can tell us about pancreatic cancer (and medical charities)

I’ve written on the growing importance of genetically modified (GM) mice in cancer research before, but it’s been a little while since I revisited the subject. So when I saw this BBC story yesterday on how scientists at the Cancer Research UK Cambridge Research Institute has used an elegant study in GM mice to identify a gene whose suppression contributes to the development of pancreatic ductal adenocarcinoma – one of the most lethal cancers – I was all set to write a blog post about it.

Then I noticed that Kat Arney at the Cancer Research Science Blog had beaten me to it, with an excellent overview of the study and its implications. I recommend that you go straight over and read her blog post.

The Nature paper describing this study can be read here.

A fascinating aspect of this work is that human genetic studies had failed to reveal the role of the Usp9x gene in pancreatic cancer, and it was only when the GM mice studies were undertaken that its importance became clear.  Does this mean that the human genetic studies were misleading? Does it mean that they were useless? Well, that would be thinking like an anti-vivisectionist.  While it’s true that the human genetic studies were initially misleading about Usp9x in pancreatic cancer, it was by combining the information from human genetic studies with that from the GM mouse studies, and the additional information from in vitro studies, that the mechanism through which Usp9x suppression contributes to the development of pancreatic cancer was revealed.

This is yet another example of the important role played by animal studies alongside  many other approaches in medical research, and I hope that it soon leads to much -needed improvments in therapy for pancreatic cancer.

There’s another aspect to this story that is almost as interesting as the science itself.  Many animal rights activists like to claim that leading medical research charities conceal their funding of animal research, indeed just the other week the animal rights activist Peter Tatchell wrote a truly execrable article in the Huffingdon Post which included the claim that:

A disturbing desire for secrecy about animal experiments is shared by a number of respected, high-profile medical charities, including the British Heart Foundation, Cancer Research UK and the Alzheimer’s Society. “

Several comments quickly pointed out that this (along with most other aspects of the article) was factually incorrect, indeed it is difficult to see how the British Heart Foundation could be more open about their animal research. So far as Cancer Research UK is concerned, perhaps somebody should ask Peter Tatchell how issuing a press release, and then discussing their animal research with the BBC and in more detail on their science blog is compatible with “desire for secrecy about animal experiments “.  I guess that Peter Tatchell isn’t one to let the facts ruin a good spin!

Paul Browne

Restoring vision in night blindness: Mice point way to stem cell therapy

Impaired vision and blindness are leading causes of disability, affecting over 3 million people in the USA today, so it’s no surprise that biomedical scientists are working hard to develop therapies to improve and restore vision.  Over the past few years we have discussed several therapies that have been developed to treat different types of vision loss, including anti-angiogenic therapies to treat wet age related macular degeneration, a leading cause of severe, irreversible vision loss in the elderly,  and gene therapy to treat Leber congenital amaurosis, an inherited disease characterised by progressive degeneration of the retina. Speaking of Research committee member Dario Ringach has also written on the Opposing Views website on the very promising research now underway to develop electronic prosthesis to restore vision in blind people.

In another important development in this field Professor Robin Ali* and his team at the UCL Institute of Ophthalmology have announced the first demonstration that transplanted retinal rod cells can improve vision in mice with night-blindness, publishing the results of their study in the prestigious science journal Nature1. Rod cells are photoreceptor cells in the retina of the eye that function well in low light conditions, and an absence of rod cells leads to night blindness. Mutations in the gene GNAT1 cause congenital night blindness in humans, and mice in which the Gnat1 gene has been knocked out are night blind.  In the video below Professor Ali show that by transplanting rod cell precursors into the retina of Gnat1 knockout mice his team was able to restore vision – albeit  not fully.

It’s a fascinating piece of work, though as Professor Ali makes clear in comments to the Guardian newspaper last week there is still a lot of work to do before this can be evaluated in humans.

Now we’ve discovered we can restore vision, it gives us impetus to go on and make the process better”

As both the video and Guardian article indicate an important step will be identifying suitable sources of cells for transplantation, with both embryonic stem cells and induced pluripotent stem (iPS) cells under consideration.  This may not take as long as one might think, as we discussed last November a clinical trial was recently launched to assess the potential for transplantation of another retinal cell type, retinal epithelial cells derived from human embryonic stem cells , to improve vision in patients with  Stargart’s Macular Dystrophy, an inherited form of blindness.

The work of Professor Ali and his colleagues at UCL is moving us closer to an effective treatment – and perhaps it is not unrealistic to talk about a cure – for night blindness. Their work will also no doubt drive research on protoreceptor cell transplantation in other forms of blindness, such as dry age related macular degeneration – the most common cause of vision loss in people aged over 50 – which is characterised by loss of both rod and cone photoreceptor cells.

Paul Browne

*        Professor Ali also played a leading role in the development of gene therapy for Leber congenital amaurosis, and led the first clinical trial of this technique.

1)      Pearson RA, Barber AC, Rizzi M, Hippert C, Xue T, West EL, Duran Y, Smith AJ, Chuang JZ, Azam SA, Luhmann UF, Benucci A, Sung CH, Bainbridge JW, Carandini M, Yau KW, Sowden JC, Ali RR. “Restoration of vision after transplantation of photoreceptors.Nature. 2012 Apr 18. doi: 10.1038/nature10997.

Mouse study points to effective treatment of Fragile X syndrome

Fragile X syndrome is the most common genetic causes of intellectual disability, affecting about 1 in 4,000 people with more males affected than females, and also the most common genetic cause of autism, being responsible for 2-6% of all cases of autism. While no drugs have yet been approved to treat Fragile X syndrome, there is considerable interest in the biomedical research community in this condition, since as well as being a significant cause of disability in its own right it is a condition whose study may well help medical science to develop effective therapies for other forms of autism.

GM mice have made crucial contributions to our understanding of Fragile X syndrome. Image courtesy of Understanding Animal Research.

Fragile X syndrome is caused by mutations that silence the Fragile X (FMR1) gene and lead to a reduction –or absence – of the fragile X mental retardation protein (FMRP) and by knocking out the corresponding Fmr1 gene in mice and other organisms scientists have been able to generate models for the evaluation of potential therapies for autistic spectrum disorders , such as the drug Arbaclofen whose development we discussed briefly in 2010.

While it was clear quite early on that FMRP plays an important role at the synapse  – the structure that allows nerve signals to be passed from one neuron to another  – the nature of that role was not obvious, though a series of experiments in a variety of animal models had indicated that a class of proteins known as the metabotropic glutamate receptors might be involved.  A key discovery was made by Professor Mark Bear at MIT, who demonstrated that FMRP acted as a counterbalance to metabotropic glutamate receptor sub-type 5 (mGluR5). mGluR5 increases protein synthesis at the synapse as a means to facilitate signal transmission through the brain, and FMRP acts to reduce protein production. In the absence of FMRP signaling at the synapse goes awry, leading to the symptoms observed in fragile X syndrome.  This key scientific breakthrough was made by Prof. Bear by genetically engineering Fmr1 knockout mice halve the production of mGluR5, resulting in a significant reduction in fragile X symptoms in these mice. This linking of alteration in the expression of the gene to changes in fragile X symptoms was an important result, indicating that it may be possible to treat Fragile X by reducing the amount or the activity of mGluR5.

However, using gene modification to knock-down mGluR5 activity in people with Fragile X syndrome is not a practical option at this time, so attention turned to identifying drugs that could block mGluR5.  Last week in a paper in the journal Neuron Prof. Bear’s team, working in collaboration with scientists at the Swiss healthcare company Roche ,announced another major breakthrough. This study used an experimental  mGluR5 inhibitor known as CTEP which had recently been shown in animal studies  to be far more selective for mGlu5 than previous mGluR5, as well as having a longer half-life in vivo making it an ideal candidate for studies where mGLuR5 activity needed to be suppressed for extended continuous periods. They showed that CTEP treatment could not only stop the worsening of the condition but actually reversed the symptoms in FMR1 knockout mice with established Fragile X syndrome (1), including hearing sensitivity, learning and memory, suggesting that the defects in Fragile X syndrome are not irreversible and that it may be possible to effectively treat the cognitive and behavioral disabilities by pharmacological inhibition of mGluR5.

While CTEP is not currently being developed for clinical use, the result of this trial adds further weight to the evidence in favor of mGluR5 inhibition as a means to treat Fragile X syndrome. Two other mGluR5 antagonists – Fenobam and STX 107 – are already being evaluated in early clinical trials following successful evaluation in Fmr1 knockout mice, and this most recent result should encourage further investment in this approach.

The discovery that symptoms can be reversed in established disease in a model of Fragile X syndrome that accurately models the disorder in humans is a major advance, suggesting that the impairments associates with autistic spectrum disorders may not always be permanent  – a result with profound implications for the future of treatment of these disorders.

Paul Browne

1)      Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L. “Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice.” Neuron. 2012 Apr 12;74(1):49-56. PubMed 22500629

sciseekclaimtoken-4f949fa5f1885

The new face of transplant surgery, thanks to animal research

Yesterday the University of Maryland Medical Center (UMM) announced most extensive full face transplant completed to date, including both jaws, teeth, and tongue. In a marathon 36-hour operation the surgical team led by Professor Eduardo Rodriguez were able to transplant a face of an anonymous donor onto their patient Richard Lee Norris, who had been injured in a gun accident 15 years ago.  The operation was the culmination of years of clinical and animal research undertaken at UMM under the leadership of Professor Stephen Bartlett, and funded by the Department of Defense and  Office of Naval Research due to its potential to help war veterans who have received serious facial injuries.

This successful operation, termed a vascularized composite allograft, was made possible not only by the selflessness of the family of the anonymous donor, but also by the years of animal research undertaken by Professors Rodriguez and Bartlett and colleagues. For example, a key factor in the success of this operation was that they transplanted high amounts of vascularized bone marrow (VBM), which came inside the transplanted jaw, a technique that was developed by the team after observing that tissue rejection following composite tissue allotransplantation in a cynomolgus monkeys was greatly reduced when VBM was included in the transplant. This discovery will also help to reduce the amount of immunosuppression that Mr. Norris and future patients require following facial transplants.

Of course this is far from the first contribution that animal research has made to transplant surgery, from the development of the techniques of kidney transplant through research in dogs by Joseph Murray and colleagues, to the careful experiments in dogs conducted by Norman Schumway and Richard Lower that led to the first successful heart transplants, to the studies in mice and rats that identified the immunosuppressive properties of the drug cyclosporin that transformed the transplantation field in the 1980′s, animal research has made a crucial contribution to this field. Indeed, in his 1990 Nobel Lecture Edward Donnall Thomas stressed the importance of animal research to his Nobel prize winning discoveries concerning bone marrow transplantation.

Finally, it should be noted that marrow grafting could not have reached clinical application without animal research, first in inbred rodents and then in outbred species, particularly the dog.”

Animal research continues to make key contributions to transplant science, and we have had several opportunities to discuss its role in the development of lab-engineered tissues for transplant, such as the artificial trachea and bladder, on this blog.

Yesterday’s news from the University of Maryland is another reminder that animal research is still crucial to advances in transplant surgery. It is also worth remembering that when animal rights groups attack animal research conducted by the Department of Defense, it is work such as that which led to yesterday’s breakthrough that they are attacking.

Paul Browne

PeTA, Celebrities and Violence

In an incident widely reported this week, the public learned that Kim Kardashian was attacked by an anti-fur activist with a bag of flour.

Normally we would not pay attention to such goings on, the sartorial debacles of minor celebrities are amusing but of little importance, and we are well aware of the ethical distinctions that exist between the use of animals in biomedical research and other uses such as food or for their fur.  However, it was later revealed that the attacker, Christina Cho, is a longtime PeTA activist. Moreover, PeTA offered to pay for her legal defense should Ms. Kardashian file any complaints against her.

On learning about these events Khloe Kardashian, Kim’s sister and longtime PeTA supporter, decided to quit the organization, writing in her blog:

I’ve been a vocal supporter of PETA for a long time [..] but I have also been very vocal about anti-bullying, so this was a huge disappointment for me. As you all know, I don’t condone violence and bullying and what happened last Thursday was just that. I am absolutely disgusted by their behavior.”

But is flour bombing the only thing that PeTA supports?  What are their limits?  Would they also pay the legal fees of someone bombing a factory farm?  What about offering legal assistance to someone that set someone’s family on fire because they are not vegetarians?  Might they also consider offering legal help to someone who teaches students how to build incendiary devices and previously bombed a university laboratory?  Oh, yes, we forgot, PeTA has already done that.

Thus, independently of the issue being debated the problem with PeTA is simple.  Frustrated by their inability to get nude celebrities – and indeed non-celebrities – to explain their moral views to the public, and being intellectually incapable of putting reasoned arguments in the court of public debate, they decide that bullying and intimidation are acceptable forms of activism. Indeed, it could even be argued that the Kardashian incident serves to distract from the more distasteful and sinister reality of what kind of organization PeTA is.

Celebrities that support PeTA should be aware that when they offer their names (and naked bodies) are also actively supporting this type of behavior. Khloe Kardashian has made a sensible decision to stay away from such organization and, perhaps, other celebrities will see the light and reconsider their support of PeTA as well.

Speaking of Research

Big Questions, but few answers from opponents of animal research

A recent edition of the BBC1 Program called “The Big Questions” offered a brief debate on animal research. Among those discussing the issues was SR’s founder, Tom Holder. Within this post we will discuss some of the many issues which were touched upon, but barely explored in this brief debate.

Some of the questions centered on moral issues, other on scientific ones. At the beginning of the discussion Prof. John Stein of Oxford University explained his use of monkeys in studying Parkinson’s disease, after which he was asked if he would experiment on great apes.  He replied he would not, unless there was some extreme circumstance that required them.

Where would you draw the line?” — countered the host.

Let us pause for a second here. This is an important question that is worth asking. But first let us consider – and reject all the theories that do not involve drawing any lines at all.  What theories are these?

One is the Cartesian view, which posits animals do not truly suffer, do not really have emotions, and do not really have interests of their own. Consequently, the Cartesian view is that humans can use animals as we please. We do not know any living scientist or philosopher that would seriously defend this view.

The other theory that does not draw any lines is the animal rights view, in which all living beings have the same basic rights to freedom and life as a normal human. Although most members of the public reject this view as making no sense at all, nobody in the panel cared to explain, nor did the host bother to ask, what justifies this stance.

What Prof. Stein articulated as a justification was a version of something called the sliding scale model.  Here, the moral weight of a living being’s interests depends on the individual’s degree of cognitive, affective and social complexity. Where we draw the line for different types of experiments in animals is a valid and important question, but we can only ask it that if we all agree with the notion of graded moral status.

Opponents of research reject such a theory.  Alistair Currie, from PeTA, stated:

Suffering is suffering.  We have a moral obligation not to impose it on anybody.”

We generally agree that unnecessary suffering should not be imposed on other living beings, and as Prof. Stein stressed, scientists work hard to ensure that suffering is eliminated or reduced to an absolute minimum in laboratory animals. We do not think there are absolute moral principles.  Even “thou shall not kill” permits exceptions, such as in the case of self defense. Another example is the infliction of harm to other human beings that was, for most of us, morally justified and necessary when it came to liberating the concentration camps in Nazi Germany.

If we truly had an absolute moral obligation to never impose suffering on anybody, as PeTA representative Currie suggests, liberating concentrations camps would be morally wrong. We might accept such a declaration from someone who is a declared pacifist, but we have plenty of evidence to suggest that PeTA is a far from being such an organization.  PeTA remains morally confused.

Invariably, when opponents of animal research fail to make an ethical case for their position, they attack the science. In this case, it was Kailah Eglington, representing the Dr Hadwen Trust, who was in charge of this strategy.

“Scientifically looking at the facts, the animal model is flawed.” — she declared without even blinking.

Wait a second. Where was she when Prof. Stein explained how he found an area of the brain that when inactivated could relieve the symptoms of Parkinson’s? How does she explain his success?  Or does she deny the benefits of the work?

Ms. Eglington also suggested that Prof. Stein could have used non-invasive methods in humans, such as MEG, suggesting the same information could be obtained by this techniques. As Prof. Stein pointed out in his response this is flatly wrong. Prof. Stein not only uses a range of such techniques, including MEG and fMRI alongside his studies in macaques, but with his colleagues at Oxford University pioneered the use of MEG as a research method in patients undergoing deep brain stimulation. However, none of the non-invasive methods can yield the same data that one obtains using micro-electrode recordings from the brain, as we discussed in an earlier post on the limitations of fMRI.

A quick visit to the Dr. Hawden Trust web-site reveals that they state with absolute certainty that:

Alternatives to animal experimentation are available in virtually every field of medical research.”

Wow…   Let’s be clear: this is complete utter nonsense that deserves to be filed here. Should we be surprised at the lack of sensible science by someone who, on the side, founded an organization which claims that “the power of positive thinking” can treat physically debilitating conditions.

Kailah Eglington furthered her pseudo-scientific nonsense by claiming that: “9 out of 10 drugs that are tested on animals successfully fail in humans“. The problem here is the mistaken blame on the animal model – these same drugs have already passed pre-clinical non-animal tests such as cell cultures and computer models; moreover, about 90% of drugs fail at every stage of development – meaning that 90% of those that pass early clinical trials in humans still fail to make it to market – this is not something we can blame the animal model for. We have previously written a full and clear rebuttal of the 90% claim – however it continues to be used by the animal rights community.

Such examples go to show a common problem for advocates of science – that it takes a lot longer to debunk junk science, than it does to make it up. While Tom Holder and Prof. Stein argued science’s case very well the debate highlighted some of the limitations of this format, though perhaps this is all we can expect from a format that tries to address Big Questions in 15 min of television programming.  It seems the goal here is more to get opposing sides to have a screaming contest rather than to provide an opportunity for thoughtful exploration of the questions at hand.

Speaking of Research

Professor Doudet vindicated as investigation rejects animal rights allegations.

Two weeks ago we discussed the targeting by Canadian animal rights group Stop UBC Animal Research (STOP) of University of British Columbia scientist Professor Doris Doudet. STOP alleged that Prof. Doudet had performed experiments on monkeys without the approval of the UBC Animal Care Committee, and then lied in a scientific paper to cover her tracks, though as we reported at the time their allegations of professional misconduct against her were based on a deliberate misrepresentation of the facts. We are now happy – though in the circumstances not very surprised – to learn that an independent investigation of Prof. Doudet’s work has dismissed the allegations made against her.

According to today’s report in the Vancouver Sun, the Canadian Council on Animal Care (CCAC) carried out a detailed review of the research undertaken by Prof. Doudet’s team, and found:

no evidence to support allegations of animal cruelty against a University of British Columbia research team related to the deaths of four macaque monkeys.”

An earlier report on CTV news adds that the CCAC investigation:

found no evidence to support allegations that UBC was subjecting monkeys to cruel research experiments that were not overseen by the UBC Animal Care Committee.”

The letter from the CCAC to STOP detailing the conclusions of their investigation can be read here.

We asked Prof Doudet her views about this week’s developments, welcoming the news she said:

It is distressing to be wrongly accused, but the truth prevailed and we are all grateful for it.  MPTP always had unexpected effects, not only in monkeys but in the humans who unknowingly injected themselves with it: Out of the more than 100 people who were exposed to the drug in the early 80s, only a handful developed severe parkinsonism and there is no way to predict who will have such a severe negative response. But the MPTP primate model and the knowledge gained from it have played an important part in the basic understanding of physiological mechanisms involved in the disease, and this has been key to the development of many therapies for Parkinson’s disease, including DBS and the current testing of many gene therapies.”

We too welcome this news, though we wonder whether a formal investigation was really required to confirm what had been patently obvious right from the start.

Speaking of Research